Research Topics
| Robert C GalloSummaryAffiliation: University of Maryland Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
A reflection on HIV/AIDS research after 25 yearsRobert C Gallo
Institute of Human Virology, University of Maryland Biotechnology Institute and Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
Retrovirology 3:72. 2006..Dr. Robert C. Gallo provides a personal reflection on the 25 year history of AIDS...
Commentary remarks on "HIV/AIDS in China"Robert C Gallo
Institute of Human Virology, University of Maryland, USA
Cell Res 15:823. 2005- History of the discoveries of the first human retroviruses: HTLV-1 and HTLV-2Robert C Gallo
Institute of Human Virology, Baltimore, MD, USA
Oncogene 24:5926-30. 2005..However, following our reports the same virus was isolated in Japan, and both groups provided evidence that HTLV-1 caused ATL, a subclassification of T-cell malignancies first recognized in Japan... - The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 yearsRobert C Gallo
Institute of Human Virology, University of Maryland Biotechnology Institute, University of Maryland Baltimore, Baltimore, MD, USA
Lancet 366:1894-8. 2005 - The discovery of the first human retrovirus: HTLV-1 and HTLV-2Robert C Gallo
Institute of Human Virology University of Maryland Biotechnology Institute 701 E, Pratt Street Baltimore, MD 21202, USA
Retrovirology 2:17. 2005..These efforts finally yielded success following the discovery of IL-2 and its use to culture adult T cell lymphoma/leukemia cells... - A journey with T cells, primate/human retroviruses and other persisting human T-cell tropic virusesRobert C Gallo
Institute of Human Virology, University of Maryland Biotechnology Institute, Department of Microbiology and Immunology and Department of Medicine, School of Medicine, 725 W Lombard Street, Baltimore, MD 21201, USA
Rev Clin Exp Hematol 7:329-35. 2003..HTLV-1, 3. HTLV-2, 4. human immunodeficiency virus and 5. human herpes virus-6 (HHV-6). This report is a brief synopsis of the discoveries of the first human retroviruses, the HTLV... - Control of HIV-1 infection by soluble factors of the immune responseAnthony L DeVico
Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, Maryland 21202, USA
Nat Rev Microbiol 2:401-13. 2004 - CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1Alonso Heredia
Institute of Human Virology, University of Maryland, 725 W Lombard Street, Baltimore, MD 21201, USA
AIDS 21:1317-22. 2007..In the present study we evaluated the impact of differences in CCR5 levels among donor CD4 T cells on the infection efficiency and T-20 susceptibility of R5 HIV-1... - Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1Alonso Heredia
Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Proc Natl Acad Sci U S A 105:20476-81. 2008.... - Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infectionYongjun Guan
Division of Basic Science, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Proc Natl Acad Sci U S A 106:3952-7. 2009..These data suggest that plasma Ab repertoires can underestimate the breadth of humoral immunity, and analyses of B(Mem) should be included in studies correlating Ab specificity with protective immunity to HIV-1... - Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitroAlonso Heredia
Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, Maryland 21201, USA
Antimicrob Agents Chemother 51:2489-96. 2007.... - Soluble factors from T cells inhibiting X4 strains of HIV are a mixture of β chemokines and RNasesFiorenza Cocchi
Institute of Human Virology and Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Proc Natl Acad Sci U S A 109:5411-6. 2012..The antiviral mechanisms of these HIV X4-suppressive factors differ from those of the previously described HIV R5-suppressive β chemokines... 
Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonistsOlga Latinovic
Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Antiviral Res 83:86-9. 2009..Combinations of RAPA and CCR5 antagonists could provide an effective means to control drug-resistant R5 HIV in patients, most notably those infected with Maraviroc-resistant viruses...- The discovery of HIV as the cause of AIDSRobert C Gallo
Institute of Human Virology, University of Maryland Biotechnology Institute and University of Maryland, Baltimore, USA
N Engl J Med 349:2283-5. 2003 - Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogensAnthony Devico
Basic Research and Vaccine and Epidemiology Divisions, Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, MD 21201, USA
Proc Natl Acad Sci U S A 104:17477-82. 2007..Collectively, these data suggest that antibodies to CD4i epitopes may play a role in controlling SHIV infection and provide insights for HIV vaccine development... - HIV-1 transgenic rat CD4+ T cells develop decreased CD28 responsiveness and suboptimal Lck tyrosine dephosphorylation following activationAnjana Yadav
Division of Basic Science, Institute of Human Virology, University of Maryland, Rm S616, 725, West Lombard Street, Baltimore, MD 21201, USA
Virology 353:357-65. 2006..These events likely lead to defects in antigen-specific signaling and may help explain the disruption of Th1 responses and the generation of specific effector/memory subsets in transgenic CD4+ T cells... - Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 bindingYongjun Guan
Division of Basic Science and Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Proc Natl Acad Sci U S A 110:E69-78. 2013..Thus, Fc-mediated effector function and neutralization coselect with specificity in anti-Env antibody responses, but the nature of selection is distinct for these two antiviral activities... - Historical essay. The early years of HIV/AIDSRobert C Gallo
Institute of Human Virology and Department of Microbiology and Immunology, University of Maryland, Baltimore, MD 21201, USA
Science 298:1728-30. 2002 - Differential polarization of immune responses by co-administration of antigens with chemokinesAchim Frauenschuh
Division of Basic Science, Institute of Human Virology, University of Maryland Biotechnology Institute, 725 West Lombard Street, Baltimore, MD 21201, USA
Vaccine 23:546-54. 2004..These results are relevant towards the engineering of novel vaccine and immune-based therapies, and point to chemokines as candidate adjuvant and immunomodulatory molecules... - Historical essay. Prospects for the futureRobert C Gallo
Institute of Human Virology and Department of Microbiology and Immunology, University of Maryland, Baltimore, MD 21201, USA
Science 298:1730-1. 2002 - Preclinical evaluation of synthetic -2 RANTES as a candidate vaginal microbicide to target CCR5Tina M Kish-Catalone
Division of Basic Sciences, Institute of Human Virology, University of Maryland Biotechnology Institute, 725 West Lombard Street, S622, Baltimore, MD 21201, USA
Antimicrob Agents Chemother 50:1497-509. 2006..Overall, these preclinical studies suggest that -2 RANTES is suitable for further testing as a candidate anti-HIV-1 microbicide... - Indirubin-3'-monoxime, a derivative of a Chinese antileukemia medicine, inhibits P-TEFb function and HIV-1 replicationAlonso Heredia
Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, Maryland 21201, USA
AIDS 19:2087-95. 2005..The drug is effective against wild-type and drug-resistant strains of HIV-1. IM may help control replication of HIV-1 in patients by disrupting a step of the HIV-1 cycle that is not being targeted in current antiretroviral treatments... - Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapyMikulas Popovic
Institute of Human Virology, University of Maryland Biotechnology Institute, University of Maryland, Baltimore, MD 21201, USA
Proc Natl Acad Sci U S A 102:14807-12. 2005.... - HIV/AIDS research after HAARTRobert C Gallo
Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, Maryland, USA
Res Initiat Treat Action 11:39-41. 2005 - HIV-1-suppressive factors are secreted by CD4+ T cells during primary immune responsesSayed F Abdelwahab
Institute of Human Virology, Biotechnology Institute, and Department of Microbiology and Immunology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA
Proc Natl Acad Sci U S A 100:15006-10. 2003..The data also suggest that production of such factors should be considered in the design of vaccines against HIV-1 and as a mechanism whereby the host can control infections with this virus... - HIV-1: a look back from 20 yearsRobert C Gallo
Institute of Human Virology, University of Maryland Biotechnology Institute and Department of Microbiology, University of Maryland Baltimore, 725 W. Lombard Street, Baltimore, MD 21201, USA
DNA Cell Biol 23:191-2. 2004 - Human retroviruses after 20 years: a perspective from the past and prospects for their future controlRobert C Gallo
Institute of Human Virology, Department of Microbiology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA
Immunol Rev 185:236-65. 2002.... - A perspective on human herpes virus 6 (HHV-6)Robert C Gallo
Institute of Human Virology, University of Maryland, Baltimore, MD, USA
J Clin Virol 37:S2. 2006 - Commentary on "Prevalence and evolution of drug resistance HIV-1 variants in Henan, China"Bruce L Gilliam
Institute of Human Virology, University of Maryland, Baltimore, MD 21201, USA
Cell Res 15:850-1. 2005 - Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartmentsDavid M Hone
Divisions of Basic Science and Vaccine Research, Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, Maryland 21201, USA
J Hum Virol 5:17-23. 2002..This paper reviews recent advances made by the authors toward the development of an HIV-1 vaccine that elicits such antibodies in both the mucosal and systemic immune compartments... - International NeuroAIDS: prospects of HIV-1 associated neurological complicationsJ Roberto Trujillo
Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, MD 21201, USA
Cell Res 15:962-9. 2005.... - HIV-1 transgenic rats develop T cell abnormalitiesWilliam Reid
Division of Basic Science, University of Maryland, Baltimore, MD 21201, USA
Virology 321:111-9. 2004.... - Sequence variation within the dominant amino terminus epitope affects antibody binding and neutralization of human immunodeficiency virus type 1 Tat proteinTracy J Ruckwardt
Institute of Human Virology, University of Maryland Biotechnology Institute, 725 W. Lombard St, Room N546, Baltimore, MD 21201, USA
J Virol 78:13190-6. 2004..Tat-neutralizing antibodies to the dominant amino terminus epitope are affected by HIV clade variation... - Research and discovery of the first human cancer virus, HTLV-1Robert C Gallo
Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Best Pract Res Clin Haematol 24:559-65. 2011.... - HIV receptors on lymphocytesAlfredo Garzino-Demo
Institute of Human Virology, University of Maryland Biotechnology Institute Baltimore, Maryland 21201, USA
Curr Opin Hematol 10:279-83. 2003..This article reviews the most exciting aspects of these novel findings and discusses their practical application in the fight against HIV infection... - Public health. A sound rationale needed for phase III HIV-1 vaccine trialsDennis R Burton
Scripps Research Institute, La Jolla, California, USA
Science 303:316. 2004 - Robert C. Gallo, M.D. [Interview by Vicki P Glaser]Robert C Gallo
J Hematother Stem Cell Res 11:751-7. 2002 - HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptorMaria A De Francesco
Institute of Microbiology, University of Brescia Medical School, 25123 Brescia, Italy
Proc Natl Acad Sci U S A 99:9972-7. 2002..Our results define a role for p17 in HIV-1 pathogenesis and contribute to our understanding of the molecular mechanism of HIV-1 infection and the development of additional antiviral therapeutic strategies... - Increased interferon alpha expression in circulating plasmacytoid dendritic cells of HIV-1-infected patientsClara Lehmann
First Department of Internal Medicine, University of Cologne, Cologne, Germany
J Acquir Immune Defic Syndr 48:522-30. 2008..On the other hand, high IFN alpha serum levels in HIV-1-infected individuals have been proposed to promote immune hyper-activation and disease progression... - Human herpesvirus 6A accelerates AIDS progression in macaquesPaolo Lusso
Unit of Human Virology, San Raffaele Scientific Institute, 20132 Milan, Italy
Proc Natl Acad Sci U S A 104:5067-72. 2007..Rapid disease development in dually infected animals was heralded by an early depletion of both CD4(+) and CD8(+) T cells. These results provide in vivo evidence that HHV-6A may act as a promoting factor in AIDS progression... - Functional and morphologic characterization of human T cells continuously grown in vitro. J. Immunol. 1977. 119: 131-138Francis W Ruscetti
J Immunol 179:1415-22. 2007 - Epilogue: a journey with blood cells and virusesRobert C Gallo
J Hematother Stem Cell Res 11:849-57. 2002 - [Kinoids: a novel generation of specific immune therapy against cytokines]Armand Bensussan
Institut National de la Sante et de la Recherche Medicale, INSERM U841, Creteil, France
Med Sci (Paris) 24:306-13. 2008..After validation by clinical trials, kinoid vaccines could represent a second generation of specific immune therapy to be used to combat ectopic cytokines... - A plea for justice for jailed medical workersSunil K Ahuja
Science 314:924-5. 2006
Research Grants
- Institute of Human Virology Annual Meeting 2002-2004Robert Gallo; Fiscal Year: 2002..abstract_text> ..
- Institute of Human Virology Annual Meeting 2005-2010Robert Gallo; Fiscal Year: 2007..abstract_text> ..